Trials / Completed
CompletedNCT04750824
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
Assessment of Real-World Outcomes Associated With Afatinib (Gilotrif) Use in Patients With Solid Tumors Harboring NRG1 Gene Fusions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 110 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afatinib | Afatinib |
| DRUG | other systemic therapy | other systemic therapy |
Timeline
- Start date
- 2020-10-15
- Primary completion
- 2021-12-20
- Completion
- 2021-12-20
- First posted
- 2021-02-11
- Last updated
- 2024-09-19
- Results posted
- 2024-09-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04750824. Inclusion in this directory is not an endorsement.